Combination therapy in the integrated treatment of recurrent chronic cystitis

Aim. To assess the results of the integrated treatment of women with recurrent chronic cystitis using the selective β3-adrenoreceptor (AR) agonist, mirabegron. Methods. The results of the treatment of women diagnosed with recurrent chronic cystitis in the urological cli­nic of KSMU were analyzed. The average age of patients was 31.5±3.4 years. To assess the effectiveness of integra­ted treatment, women with recurrent chronic cystitis were randomly divided into two groups: the first group (30 patients) who received antibiotic therapy in combination with the drug mirabegron at a dose of 50 mg once a day and the second (control) group (30 patients), who received antibiotic therapy taking into account their susceptibility. All patients underwent ultrasonography of the genitourinary system, urodynamic studies with assessment of the ma­ximum urinary flow, average urinary flow, bacterial urine cultures. Results. Analysis of the research results showed a greater reduction in the number of urinations per day (up to 7 times) in the first group. The frequency of urinary urgency decreased in 82.6% of the first group patients compared to 64% of the second group (p <0.05). In the combination therapy versus control groups, there was reduced hospital stay by an average of 4 days (11.2 vs 15 days; p <0.05). On the 15th day of treatment, control cystoscopy revealed no changes in the bladder mucosa in all patients of the first group. Also, in the first group of patients, there was a greater improvement in urodynamic parameters compared to the control group (p <0.05). Conclusion. The selective β3-AR agonist mirabegron used in the integrated treatment of recurrent chronic cystitis increases the effectiveness of the therapy.